30 years of historical data (1995–2024) · Healthcare · Drug Manufacturers - General
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Bristol-Myers Squibb Company currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 9.1x P/FCF, 8% below the 5-year average of 9.9x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $127.0B | $114.6B | $106.6B | $154.4B | $140.0B | $140.1B | $109.9B | $85.1B | $101.2B | $98.2B | $115.5B |
| Enterprise Value | $167.9B | $155.5B | $136.6B | $186.0B | $171.6B | $177.2B | $145.1B | $85.5B | $103.8B | $100.7B | $119.8B |
| P/E Ratio → | -14.14 | — | 13.29 | 24.39 | 19.98 | — | 31.94 | 17.16 | 100.46 | 22.05 | 70.92 |
| P/S Ratio | 2.63 | 2.37 | 2.37 | 3.35 | 3.02 | 3.29 | 4.20 | 3.77 | 4.87 | 5.05 | 6.97 |
| P/B Ratio | 7.71 | 7.00 | 3.62 | 4.96 | 3.89 | 3.70 | 2.13 | 6.02 | 8.55 | 6.01 | 8.01 |
| P/FCF | 9.11 | 8.22 | 8.43 | 12.92 | 9.19 | 10.53 | 14.90 | 13.92 | 23.99 | 53.27 | 89.88 |
| P/OCF | 8.36 | 7.55 | 7.69 | 11.82 | 8.64 | 9.97 | 13.39 | 12.04 | 19.19 | 32.11 | 54.87 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Bristol-Myers Squibb Company's enterprise value stands at 8.7x EBITDA, roughly in line with its 5-year average of 9.1x. The Healthcare sector median is 13.8x, placing the stock at a 37% discount on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.22 | 3.04 | 4.03 | 3.70 | 4.17 | 5.55 | 3.79 | 4.99 | 5.18 | 7.23 |
| EV / EBITDA | 8.72 | 8.07 | 7.49 | 9.52 | 8.48 | 11.91 | 17.73 | 12.16 | 17.22 | 18.10 | 27.77 |
| EV / EBIT | 17.38 | — | 14.22 | 20.79 | 18.19 | — | 25.77 | 13.90 | 19.48 | 16.55 | 52.99 |
| EV / FCF | — | 11.15 | 10.80 | 15.57 | 11.26 | 13.32 | 19.68 | 13.99 | 24.59 | 54.61 | 93.23 |
Margins and return-on-capital ratios measuring operating efficiency
Bristol-Myers Squibb Company earns an operating margin of 20.0%. A negative ROE of -39.0% indicates the company is currently destroying shareholder equity. ROIC of 12.4% represents solid returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.8% | 56.8% | 56.3% | 57.4% | 57.7% | 51.0% | 66.0% | 71.3% | 72.0% | 74.6% | 77.3% |
| Operating Margin | 20.0% | 20.0% | 18.8% | 20.1% | 20.6% | 10.6% | 24.6% | 28.3% | 25.2% | 26.7% | 23.8% |
| Net Profit Margin | -18.5% | -18.5% | 17.8% | 13.7% | 15.1% | -21.2% | 13.2% | 21.8% | 4.8% | 22.9% | 9.5% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -39.0% | -39.0% | 26.5% | 18.9% | 18.9% | -20.1% | 10.4% | 37.9% | 7.1% | 29.0% | 10.6% |
| ROA | -9.5% | -9.5% | 8.4% | 6.1% | 6.1% | -7.2% | 4.2% | 14.4% | 3.0% | 13.6% | 4.8% |
| ROIC | 12.4% | 12.4% | 10.4% | 10.7% | 10.0% | 4.2% | 9.5% | 33.1% | 23.7% | 20.7% | 16.4% |
| ROCE | 13.6% | 13.6% | 11.5% | 11.4% | 10.2% | 4.3% | 9.5% | 26.5% | 21.4% | 21.3% | 16.1% |
Solvency and debt-coverage ratios — lower is generally safer
Bristol-Myers Squibb Company carries a Debt/EBITDA ratio of 2.7x, which is moderately leveraged (15% below the sector average of 3.1x). Net debt stands at $40.9B ($51.2B total debt minus $10.3B cash). Interest coverage of 5.0x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.12 | 3.12 | 1.41 | 1.31 | 1.27 | 1.36 | 0.92 | 0.52 | 0.67 | 0.41 | 0.46 |
| Debt / EBITDA | 2.66 | 2.66 | 2.27 | 2.08 | 2.25 | 3.47 | 5.81 | 1.05 | 1.32 | 1.21 | 1.55 |
| Net Debt / Equity | — | 2.49 | 1.02 | 1.02 | 0.88 | 0.98 | 0.68 | 0.03 | 0.21 | 0.15 | 0.30 |
| Net Debt / EBITDA | 2.12 | 2.12 | 1.65 | 1.62 | 1.56 | 2.50 | 4.30 | 0.06 | 0.42 | 0.44 | 1.00 |
| Debt / FCF | — | 2.93 | 2.37 | 2.64 | 2.08 | 2.79 | 4.77 | 0.07 | 0.60 | 1.34 | 3.35 |
| Interest Coverage | 4.96 | 4.96 | 7.27 | 7.53 | 7.15 | 3.16 | 9.82 | 34.94 | 26.73 | 31.01 | 21.40 |
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.25x means Bristol-Myers Squibb Company can comfortably meet its short-term obligations, though there is limited excess liquidity.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.25 | 1.25 | 1.43 | 1.25 | 1.52 | 1.58 | 1.60 | 1.66 | 1.55 | 1.55 | 1.30 |
| Quick Ratio | 1.15 | 1.15 | 1.31 | 1.14 | 1.43 | 1.47 | 1.37 | 1.55 | 1.43 | 1.41 | 1.15 |
| Cash Ratio | 0.46 | 0.46 | 0.55 | 0.42 | 0.79 | 0.86 | 0.84 | 0.82 | 0.71 | 0.72 | 0.53 |
| Asset Turnover | — | 0.52 | 0.47 | 0.48 | 0.42 | 0.36 | 0.20 | 0.64 | 0.62 | 0.58 | 0.52 |
| Inventory Turnover | 8.16 | 8.16 | 7.38 | 8.41 | 9.37 | 10.04 | 2.07 | 5.43 | 4.99 | 3.97 | 3.07 |
| Days Sales Outstanding | — | 109.00 | 123.79 | 110.21 | 98.49 | 90.60 | 107.29 | 92.98 | 110.68 | 104.14 | 94.75 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Bristol-Myers Squibb Company returns 3.8% to shareholders annually primarily through dividends.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 3.8% | 4.2% | 4.4% | 3.0% | 3.1% | 2.9% | 2.4% | 3.1% | 2.5% | 2.6% | 2.1% |
| Payout Ratio | — | — | 59.1% | 73.2% | 62.9% | — | 77.9% | 53.1% | 255.9% | 57.1% | 158.3% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 7.5% | 4.1% | 5.0% | — | 3.1% | 5.8% | 1.0% | 4.5% | 1.4% |
| FCF Yield | 11.0% | 12.2% | 11.9% | 7.7% | 10.9% | 9.5% | 6.7% | 7.2% | 4.2% | 1.9% | 1.1% |
| Buyback Yield | 0.0% | 0.0% | 4.8% | 5.2% | 4.5% | 1.1% | 6.6% | 0.4% | 2.4% | 0.2% | 0.0% |
| Total Shareholder Yield | 3.8% | 4.2% | 9.3% | 8.2% | 7.6% | 4.0% | 9.1% | 3.4% | 5.0% | 2.8% | 2.1% |
| Shares Outstanding | — | $2.0B | $2.1B | $2.1B | $2.2B | $2.3B | $1.7B | $1.6B | $1.7B | $1.7B | $1.7B |
Compare BMY with 3 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| BMYYou | $127B | -14.1 | 8.7 | 9.1 | 56.8% | 20.0% | -39.0% | 12.4% | 2.7 |
| LLY | $942B | 89.9 | 50.5 | 2273.1 | 81.3% | 38.9% | 84.3% | 33.7% | 1.7 |
| JNJ | $599B | 42.9 | 20.7 | 30.2 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
| AZN | $323B | 63.7 | 17.8 | 27.5 | 81.9% | 23.4% | 22.9% | 14.9% | 1.5 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 30 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how BMY stacks up against sector leader Eli Lilly and Company.
Start ComparisonBristol-Myers Squibb Company's current P/E ratio is -14.1x. The historical average is 27.9x.
Bristol-Myers Squibb Company's current EV/EBITDA is 8.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 14.3x.
Bristol-Myers Squibb Company's return on equity (ROE) is -39.0%. The historical average is 26.1%.
Based on historical data, Bristol-Myers Squibb Company is trading at a P/E of -14.1x. Compare with industry peers and growth rates for a complete picture.
Bristol-Myers Squibb Company's current dividend yield is 3.85%.
Bristol-Myers Squibb Company has 56.8% gross margin and 20.0% operating margin. Operating margin between 10-20% is typical for established companies.
Bristol-Myers Squibb Company's Debt/EBITDA ratio is 2.7x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.